

Appendix I—Hepatitis C Training Programs for Substance Abuse Treatment Program Staff

Focus on Hepatitis C was developed by the Hepatitis C Association, sponsored by the Substance Abuse and Mental Health Services Administration. The 3-hour training includes a PowerPoint presentation, a question-and-answer session, and a discussion of local resources. Content includes functions of the liver, risk factors, modes of transmission, diagnostic process and treatment of HCV, natural history and progression of HCV and HCV/HIV co-infection, healthful lifestyle choices that preserve liver health, counseling guidelines, and issues and challenges in providing care for clients with hepatitis C in treatment centers. Training provides information on locating community resources; Web sites, toll-free support lines, and venues for medical care; and information on obtaining treatment assistance for people who are not insured or are underinsured. Continuing education credits can be earned (<http://www.hepcfocus.com>).

- The **Centers for Disease Control and Prevention** (CDC) maintains numerous trainings and resources (<http://www.cdc.gov/ncidod/diseases/hepatitis/resource/training/counseling.htm>).
- **HCV Advocate** offers training resources and information from the client's perspective (http://www.hcvadvocate.org/hepatitis/training_resources.asp).
- **CDC's Division of Viral Hepatitis** provides funding to HCV coordinators across the country to offer viral hepatitis counseling, testing, vaccinations, and other services (<http://www.cdc.gov/hepatitis/index.htm>).
- Pharmaceutical manufacturers of hepatitis medications are often willing to conduct free onsite training sessions for counseling staff. Contact manufacturers directly.

Appendix J—Stakeholders Meeting Participants

Cheryl Anderson

Bureau of Primary Health Care
Quality Improvement
Health Resources and Services
Administration
Rockville, Maryland

Joanna Buffington, M.D., M.P.H.

Medical Officer
Prevention Branch, Division of Viral
Hepatitis
Centers for Disease Control and
Prevention
Atlanta, Georgia

**H. Westley Clark, M.D., J.D.,
M.P.H., CAS, FASAM**

Director
Center for Substance Abuse Treatment
Substance Abuse and Mental Health
Services Administration
Rockville, Maryland

Edwin M. Craft, Dr.P.H.

Lead Government Project Officer,
Methamphetamine
Center for Substance Abuse Treatment
Substance Abuse and Mental Health
Services Administration
Rockville, Maryland

Christina Currier

Government Project Officer
Center for Substance Abuse Treatment
Substance Abuse and Mental Health
Services Administration
Rockville, Maryland

David A. Fiellin, M.D., Chair

Professor of Medicine and of Public
Health and Associate Professor of
Investigative Medicine
Yale University School of Medicine
New Haven, Connecticut

Robert Hendricks

Special Assistant to the Director
Center for Substance Abuse Treatment
Substance Abuse and Mental Health
Services Administration
Rockville, Maryland

Warren Hewett, Jr.

AIDS Coordinator
Center for Substance Abuse Treatment
Substance Abuse and Mental Health
Services Administration
Rockville, Maryland

Kirk E. James, M.D.

Medical Officer
Systems Improvement Branch
Center for Substance Abuse Treatment
Substance Abuse and Mental Health Services
Administration
Rockville, Maryland

Leslye D. Johnson, Ph.D.

Chief, Enteric and Hepatic Diseases Branch
Division of Microbiology and Infectious
Diseases
National Institute of Allergy and Infectious
Diseases
National Institutes of Health
Bethesda, Maryland

Stella P. Jones, M.S.W., LICSW, BCD

Senior Program Management Officer
Center for Substance Abuse Treatment
Substance Abuse and Mental Health Services
Administration
Rockville, Maryland

Jag H. Khalsa, Ph.D.

Chief, Medical Consequences Branch, DPMC
National Institute on Drug Abuse
National Institutes of Health
Bethesda, Maryland

Andrea Kopstein, Ph.D., M.P.H.

Practice Improvement Branch Chief
Division of Services Improvement
Center for Substance Abuse Treatment
Substance Abuse and Mental Health Services
Administration
Rockville, Maryland

Thomas F. Kresina, Ph.D.

Senior Public Health Advisor
Division of Pharmacologic Therapies
Center for Substance Abuse Treatment
Substance Abuse and Mental Health Services
Administration
Rockville, Maryland

Robert Lubran, M.S., M.P.A.

Director
Division of Pharmacologic Therapies
Center for Substance Abuse Treatment
Substance Abuse and Mental Health Services
Administration
Rockville, Maryland

Eileen M. McGrath, J.D.

Executive Vice President
American Society of Addiction Medicine
Chevy Chase, Maryland

Shirley Mikell

NAADAC—The Association for Addiction
Professionals
Alexandria, Virginia

Daniel Raymond

Policy Director
Harm Reduction Coalition
New York, New York

Leonard B. Seeff, M.D.

Senior Scientist for Hepatitis Research
National Institute of Diabetes and Digestive
and Kidney Diseases
National Institutes of Health
Bethesda, Maryland

Dennis Simon

Secretary/Treasurer
Hepatitis C Association
Scotch Plains, New Jersey

Jack Stein, M.S.W., Ph.D.

Director
Division of Services Improvement
Center for Substance Abuse Treatment
Substance Abuse and Mental Health Services
Administration
Rockville, Maryland

Chris Taylor

Viral Hepatitis Program Manager
National Alliance of State and Territorial
AIDS Directors
Washington, D.C.

Thelma King Thiel, RN

Chair and Chief Executive Officer
Hepatitis Foundation International
Silver Spring, Maryland

David C. Thompson

HIV/AIDS Team Leader
Center for Substance Abuse Treatment
Substance Abuse and Mental Health Services
Administration
Rockville, Maryland

Mary R. Vienna

Health Resources and Services Administration
Rockville, Maryland

Appendix K—Field Reviewers

Corinna Dan, RN, M.P.H.

Hepatitis Foundation International
Silver Spring, Maryland

Brenda Davis

Clinic Manager
Beth Israel Medical Center
Methadone Maintenance Treatment
Program
New York, New York

Leonard Gill

President, HCV Peer Educator/
Patient Advisory Committee
Albert Einstein College of Medicine
Division of Substance Abuse
Bronx, New York

Carol L. Kuprevich, Ed.D.

Director of Community Planning,
Program Development, and
Training
Delaware Division of Alcohol,
Drug Abuse and Mental Health
New Castle, Delaware

Shirley Mikell

NAADAC—The Association for
Addiction Professionals
Alexandria, Virginia

Rosa Rodriguez

Substance Abuse Counselor
Albert Einstein College of Medicine
Peekskill, New York

Leonard B. Seeff, M.D.

Senior Scientist for Hepatitis
Research
National Institute of Diabetes and
Digestive and Kidney Diseases,
Division of Digestive Diseases and
Nutrition
National Institutes of Health
Bethesda, Maryland

Carol Sholiton

President and Founder
Methadone Support Org
Scottsdale, Arizona

**Dee-Dee Stout, M.A., CADC II,
MINT**

Director
Responsible Recovery
Emeryville, California

Lynn E. Sullivan, M.D.

Assistant Professor of Medicine
Yale University
New Haven, Connecticut

Lynn E. Taylor, M.D.

Assistant Professor of Medicine
The Warren Alpert Medical School of Brown
University
Providence, Rhode Island

Thelma King Thiel, RN

Chair and Chief Executive Officer
Hepatitis Foundation International
Silver Spring, Maryland

Jeanne Wells

Social Worker
Rocky Mountain Health Services
Woodland Park, Colorado

Kimberly Wright

Medical Services Coordinator
Missouri RAIN
Columbia, Missouri
and
National Institute of Diabetes and
Digestive and Kidney Diseases
National Institutes of Health
Bethesda, Maryland

Appendix L— Acknowledgments

Numerous people contributed to the development of this Treatment Improvement Protocol (TIP), including the TIP Consensus Panel (p. xiii), stakeholders (Appendix J), and field reviewers (Appendix K).

This publication was written and produced under contract numbers 270-04-7049 and 270-09-0307, by the Knowledge Application Program (KAP), a Joint Venture of JBS International, Inc., and The CDM Group, Inc., for the Center for Substance Abuse Treatment (CSAT), Substance Abuse and Mental Health Services Administration (SAMHSA), U.S. Department of Health and Human Services (HHS).

Lynne MacArthur, M.A., A.M.L.S., served as the JBS KAP Executive Project Co-Director, and Barbara Fink, RN, M.P.H., served as the JBS KAP Managing Project Co-Director. Other JBS KAP personnel included Candace Baker, M.S.W., MAC, Deputy Director for Product Development; Deborah Steinbach, M.A., Senior Writer; Patricia Kassebaum, M.A., Senior Writer; Kris Rusch, M.A., Senior Writer; Martha J. Horn, Ph.D., Senior Writer; Frances Nebesky, M.A., Quality Assurance Editor; Wendy Caron, Quality Assurance Manager; Erin P. Doherty, Copy Editor; Terrie Young, Graphic Designer; and Erin Sandor, Graphic Designer.

Index

A

- Acupuncture, 46, 105
- Acute hepatitis, 4, 6, 7, 8, 42
- Adefovir dipivoxil, 41, 87
- Administrators' guide
 - education, 65–66
 - funding comprehensive services, 63
 - integrating interventions with HIV services, 68
 - legal and ethical issues, 71
 - medical evaluation and diagnosis, 62
 - outreach activities, 66–68
 - policies and procedures development, 69
 - prevention and vaccination, 65
 - program assessment and planning, 61–62
 - program evaluation, 69
 - screening for hepatitis, 62
 - successful implementation, 70–71
 - support services, 66, 68
 - treatment guidelines, 62–66
- Affective disorders, 105
- AIDS. *See* HIV co-infection
- Alcohol abuse
 - hepatitis treatment and, 34
- Alternative medicine, 46, 99–100
- American Association for the Study of Liver Diseases Guidelines, 33, 64
- Anemia
 - as treatment side effect, 44
- Antibodies, 13, 14, 15, 16, 22, 87, 89
- Antigens, 13, 14, 22, 87
- Antiviral treatment, 3, 20, 25–29, 31–38, 40–50, 53, 55, 57
- Anxiety disorders, 105

B

- Behavioral health disorders
 - counseling, 37, 47, 67, 101–102, 109
 - hepatitis treatment and, 49–50

- Biopsy, liver, 23, 27–29, 45, 63
 Boceprevir, 25, 26, 43, 87, 107, 108
- C**
- CAM. *See* Complementary or alternative medicine
- Case management, 57–58, 102, 106
- CDC. *See* Centers for Disease Control and Prevention
- Center for Substance Abuse Treatment, ii, vii, xi, 58, 62, 106, 109, 115–117, 121
- Centers for Disease Control and Prevention, 5, 6, 8, 14, 15, 62, 64, 91, 113, 115
- Chronic hepatitis
 genotype test, 25–26
 liver biopsy, 27–29
 liver panel, 23–24
 symptoms of, 4
 treatment counseling, 35–36, 42
 treatment guidelines, 62–66
 viral load tests, 24–25
- Cirrhosis, 1, 4, 6, 8, 11, 12, 24, 27, 32, 88
- Client counseling. *See* Counseling approaches
- Client education, 66
- Combating the Silent Epidemic of Viral Hepatitis: U.S. Department of Health and Human Services Action Plan for the Prevention, Care and Treatment of Viral Hepatitis*, 2
- Complementary or alternative medicine, 46, 99–100
- Confidentiality issues, 64, 67, 71, 72
- Consensus Panel, viii, ix, 7, 16, 65, 121
- Counseling approaches
 addressing relapse, 55–56, 102
 building therapeutic relationship, 52
 case management, 57–58
 confronting social factors, 54–55
 developing prevention plans, 54
 ensuring safety, 52
 helping clients understand diagnoses, 53
 hepatitis B, 42
 hepatitis education, 10, 18–19
 liver biopsy decision, 27–28
 motivational approaches, 48, 54, 59, 102, 104, 109
 providing reliable information, 52, 102
 resources, 109
 risky behavior, 16, 18, 19, 46, 54, 67
 screening process, 15–21
 strategies, 51, 52
 substance abuse treatment planning, 53
 support systems, 56–57
 treatment based on HCV status, 35–36
 treatment decisions, 31, 35–37, 42
- CSAT. *See* Center for Substance Abuse Treatment
- D**
- Deoxyribonucleic acid tests, 24, 88
- Depression, 32, 34, 41, 44, 49, 50, 53, 55, 59, 68, 102, 103–105
 hepatitis treatment considerations, 34
 as treatment side effect, 44
- Dietary supplements, 46, 99–100
- DNA tests, 24
- Drug interactions, 105, 106–108
- E**
- Educate–Motivate–Facilitate groups, 68
- Education activities, 38, 48, 51, 52, 61, 63, 65–66, 69, 91, 92, 93, 104, 113
- End-stage liver disease, 32, 36, 42, 46, 49, 88
- Entecavir, 40, 41, 50
- Ethical issues, 71
- Ethnicity
 impact on hepatitis treatment, 35, 37
- Eye disorders
 as treatment side effect, 44
- F**
- Family support, 57, 59
- FDA. *See* U.S. Food and Drug Administration
- Fibrosis, 4, 8, 27, 36, 88
- Financial assistance sources, 111
- Focus on Hepatitis C, 113

G

Genotypes

- impact on hepatitis treatment, 34
- tests, 23, 25–26

Glossary, 87–90

HHAV. *See* Hepatitis AHBV. *See* Hepatitis BHCV. *See* Hepatitis C

HCV Advocate, 113

HDV. *See* Hepatitis D virus

Health Insurance Portability and Accountability Act, 71

Hepatitis

- causes of, 3

Hepatitis, acute, 4, 24

Hepatitis, chronic

- genotype test, 25–26
- liver biopsy, 27–29
- liver panel, 23–24
- symptoms of, 4
- treatment counseling, 35–36
- treatment guidelines, 62–66
- viral load tests, 24–25

Hepatitis, viral. *See also* Counseling approaches

- causes of, 3
- co-infections, 3–4, 10–11
- interagency working group, 1–2
- liver damage, 4
- medical evaluation, 23–29
- program services, 61–72
- screening process, 13–22, 62
- symptoms, 4
- treatment, 39–50, 62–66
- treatment decisions, 31–38
- types of, 3–4, 10

Hepatitis A

- course of disease, 5
- disease burden, 5
- duration of illness, 4–5
- HIV co-infection, 11
- modes of transmission, 5
- overview, 3–4

- prevention of infection, 5–6

- screening process, 14

- substance use and, 5

- treatment for, 40

- vaccination, 65

Hepatitis B

- course of disease, 6–7

- disease burden, 6

- HIV co-infection, 11

- modes of transmission, 6

- overview, 3–4

- prevention of infection, 7

- screening process, 14

- substance use and, 7

- treatment for, 40–42

- vaccination, 65

Hepatitis C Association, 113

Hepatitis C

- antiviral treatment, 42–44, 95–97

- course of disease, 8–9

- disease burden, 8

- duration of illness, 7–8

- HIV co-infection, 11, 48–49

- mental health treatment considerations, 101–108

- modes of transmission, 8

- overview, 3–4

- prevention of infection, 9

- screening process, 14–15

- substance use and, 9

- treatment counseling, 35–36

- treatment for, 40, 42–49

- treatment response classifications, 34

Hepatitis D virus, 10

Hepatitis E virus, 10

Hepatitis F virus, 10

Hepatitis G virus, 10

Herbal treatments, 46, 99–100

HEV. *See* Hepatitis E virusHFV. *See* Hepatitis F virusHGV. *See* Hepatitis G virusHHS. *See* U.S. Department of Health and Human ServicesHIPAA. *See* Health Insurance Portability and Accountability Act

- HIV co-infection
 integrating hepatitis interventions with existing services, 68
 treatment issues, 11, 35, 45, 48–49
- I**
 IDU. *See* Injection drug use
Implementing Change in Substance Abuse Treatment Programs, 62
 Informed consent, 29, 71–72
 Injection drug use, 1, 6, 8, 15, 17, 34, 48, 54, 65, 104
 Institute of Medicine, 1, 4, 8, 62
 Interferon, 25, 32, 41, 43, 89, 96, 104, 106–108
 IOM. *See* Institute of Medicine
- K**
 KAP Keys, 123
 Knowledge Application Program, ii, viii, 121, 123
- L**
 Lamivudine, 41, 89
 Legal issues, 67, 71
 LFTs. *See* Liver function tests
 Liver
 biopsy, 23, 27–29, 45, 63
 function of, 3
 hepatitis damage, 4, 35
 Liver function tests, 23–24
 Liver panel, 23–24
 Liver transplantation, 36, 42, 45–46
- M**
 Mania
 as treatment side effect, 44
 MAT. *See* Medication-assisted treatment
 Medication. *See* Treatment
 Medication-assisted treatment, 37, 45, 46–47, 58, 62
 Medicinal plant treatments, 46, 99–100
 Men who have sex with men, 5, 7
 Mental health disorders
 affective disorders, 105
 anxiety disorders, 105
 behavioral health counseling, 101–102
 effects of antiviral treatment, 103–104
 hepatitis treatment and, 49–50
 psychiatric assessment, 103
 serious mental illness, 106–108
 suicidality, 34, 104, 105–106
 treatment readiness, 102–103
 Minneapolis Healthy Liver Program, 70
 Motivational approaches, 54, 102, 109
 MSM. *See* Men who have sex with men
 Multidisciplinary teams, 64
- N**
 NASTAD. *See* National Alliance of State and Territorial AIDS Directors
 National Alliance of State and Territorial AIDS Directors, 65
 National Institutes of Health Consensus Statement, 33
 Neutropenia
 as treatment side effect, 44
 New York State Department of Health Guidelines, 33
 Nucleic acid tests, 24
- O**
 OASIS. *See* Organization to Achieve Solutions in Substance-Abuse
 Onsite treatment, 63–64
 Opioid dependence
 hepatitis treatment and, 34, 37, 45, 46–47, 107
 Opioid treatment programs, 47, 62, 65
 Organization to Achieve Solutions in Substance-Abuse, 68
 OTP. *See* Opioid treatment program
 Outreach activities, 66–68
- P**
 Peer counseling, 56–57, 68
 Practice Guidelines of the American Association for the Study of Liver Diseases, 33, 64
 Pregnancy
 antiviral treatment considerations, 32, 33, 53

- Prevention activities, 5–7, 9, 54, 65
 - Privacy issues, 71
 - Program services
 - education, 65–66
 - evaluation of, 69
 - funding comprehensive services, 63
 - integrating interventions with HIV services, 68
 - legal and ethical issues, 71
 - medical evaluation and diagnosis, 62
 - outreach activities, 66–68
 - policies and procedures development, 69
 - prevention and vaccination, 65
 - screening for hepatitis, 62
 - successful implementation, 70–71
 - support services, 33, 61, 66, 68, 70, 94
 - treatment guidelines, 62–66
 - Project Samaritan Health Services, 63
 - Psychiatric assessment, 103
 - Pulmonary disorders
 - as treatment side effect, 44
- Q**
- Quick Guide, 123
- R**
- Referrals, 19, 38, 47, 57, 64
 - Resources, 91–94, 109
 - Ribavirin, 25, 26, 32, 33, 39, 43, 44, 89, 96, 97, 106
 - Ribonucleic acid tests, 15, 24
 - Risky behavior, 16, 18, 19, 22, 46, 54, 67
 - RNA tests, 15, 24
- S**
- SAMHSA. *See* Substance Abuse and Mental Health Services Administration
 - Screening process
 - antigens and antibodies, 13
 - client counseling, 15–21
 - hepatitis A, 14
 - hepatitis B, 14
 - hepatitis C, 14–15
 - program services, 62
 - results, 20–21
 - staff training, 69
 - treatment program's role, 13
 - Serious mental illness, 106–108
 - Services. *See* Program services
 - SMI. *See* Serious mental illness
 - Social factors, 54–55
 - Spleen, 4
 - Staff education, 66–67, 69, 113
 - Staff member rights, 71
 - Substance Abuse and Mental Health Services Administration
 - Focus on Hepatitis C, 113
 - general, ii, vii, viii, xi, 64, 106, 115–117, 121
 - publications ordering, 123
 - website, 64
 - Substance use disorders. *See also* Program services
 - counseling strategies, 51
 - hepatitis risk, 1, 5, 7, 9
 - opioid dependence and hepatitis treatment, 34, 46–47
 - relapses, 47–48, 55–56, 64
 - treatment planning, 53
 - SUDs. *See* Substance use disorders
 - Suicidality, 34, 104, 105–106
 - Superinfection, 10
 - Support groups, 56
 - Support services, 56–57, 66, 68
 - Sustained virologic response, 34, 42–43
 - SVR. *See* Sustained virologic response
- T**
- TAP 31. *See* Technical Assistance Publication, 31
 - Technical Assistance Publication, 31, 62
 - Telaprevir, 25, 26, 43
 - Telbivudine, 41, 90
 - Tenofovir, 40, 41, 50, 90
 - Terminology, 2–3
 - TIPS. *See* Treatment Improvement Protocols
 - Training. *See* Staff education
 - Transplantation, liver, 36, 42, 45–46
 - Treatment
 - adherence to, 33–34, 35, 36, 44, 47, 49, 53, 58, 64, 65, 67, 68, 103, 104, 106
 - antiviral, 42–44

- barriers to, 37–38, 49, 52, 67
 - for behavioral health disorders, 105–106, 101–108
 - behavioral health disorders and, 49–50
 - complementary or alternative medicine, 46, 99–100
 - contraindications, 32–33
 - counselor’s role, 31
 - deferring, 44–45
 - drug interactions, 106–108
 - effects of antiviral treatment on behavioral health, 103–104
 - guidelines, 46, 62–66
 - health problems and, 33, 44
 - for hepatitis A, 40
 - for hepatitis B, 40–42
 - for hepatitis C, 40, 42–49
 - HIV co-infection and, 48–49, 113
 - likelihood of success, 34–35
 - liver transplantation, 36, 42, 45–46
 - multidisciplinary teams, 64
 - onsite, 63–64
 - opioid dependence and, 34, 37, 45, 46–47
 - options, 2, 31–32, 36, 39, 42, 48
 - pregnancy and, 32, 33, 53
 - readiness for, 102–103
 - recommendations, 39–40
 - referral to hepatitis treatment providers, 64
 - response classifications, 34
 - side effects, 27, 28, 36, 37, 39, 40, 43–44, 46, 47, 95–97
 - supporting decisions, 36–37
 - timing of, 32
 - Treatment Improvement Protocols
 - audience for, 2
 - development process, viii
 - format, vii–viii
 - purpose of, 2, 123
 - terminology, 2–3
 - website, vii
 - Twinrix, 7, 65
- U**
- U.S. Department of Health and Human Services
 - interagency working group on viral hepatitis, 1–2
 - U.S. Department of Veterans Affairs, 56, 64
 - U.S. Food and Drug Administration, 15, 25, 65, 87, 89, 90, 105, 108
- V**
- Vaccination, 1, 5, 6, 7, 10, 12, 16, 20, 21, 35, 36, 40, 54, 61, 62, 65, 67, 70, 71, 113
 - Viral hepatitis. *See* Hepatitis, viral
 - Viral Hepatitis Action Plan, 2
 - Viral load
 - impact on hepatitis treatment, 34
 - tests, 24–25
 - Virologic relapses, 34

CSAT TIPs and Publications Based on TIPs

What Is a TIP?

Treatment Improvement Protocols (TIPs) are the products of a systematic and innovative process that brings together clinicians, researchers, program managers, policymakers, and other Federal and non-Federal experts to reach consensus on state-of-the-art treatment practices. TIPs are developed under CSAT's Knowledge Application Program to improve the treatment capabilities of the Nation's alcohol and drug abuse treatment service system.

What Is a Quick Guide?

A Quick Guide clearly and concisely presents the primary information from a TIP in a pocket-sized booklet. Each Quick Guide is divided into sections to help readers quickly locate relevant material. Some contain glossaries of terms or lists of resources. Page numbers from the original TIP are referenced so providers can refer back to the source document for more information.

What Are KAP Keys?

Also based on TIPs, KAP Keys are handy, durable tools. Keys may include assessment or screening instruments, checklists, and summaries of treatment phases. Printed on coated paper, each KAP Keys set is fastened together with a key ring and can be kept within a treatment provider's reach and consulted frequently. The Keys allow you—the busy clinician or program administrator—to locate information easily and to use this information to enhance treatment services.

Ordering Information

Publications may be ordered for free at <http://store.samhsa.gov>. To order over the phone, please call 1-877-SAMHSA-7 (1-877-726-4727) (English and Español). Most publications can also be downloaded at <http://www.kap.samhsa.gov>.

- | | |
|--|---|
| <p>TIP 1 State Methadone Treatment Guidelines—
<i>Replaced by TIP 43</i></p> <p>TIP 2* Pregnant, Substance-Using Women—
BKD107</p> <p>TIP 3 Screening and Assessment of Alcohol- and Other Drug-Abusing Adolescents—<i>Replaced by TIP 31</i></p> <p>TIP 4 Guidelines for the Treatment of Alcohol- and Other Drug-Abusing Adolescents—
<i>Replaced by TIP 32</i></p> <p>TIP 5 Improving Treatment for Drug-Exposed Infants—BKD110</p> <p>TIP 6* Screening for Infectious Diseases Among Substance Abusers—BKD131
Quick Guide for Clinicians QGCT06
KAP Keys for Clinicians KAPT06</p> <p>TIP 7 Screening and Assessment for Alcohol and Other Drug Abuse Among Adults in the Criminal Justice System—<i>Replaced by TIP 44</i></p> <p>TIP 8 Intensive Outpatient Treatment for Alcohol and Other Drug Abuse—<i>Replaced by TIPs 46 and 47</i></p> | <p>TIP 9 Assessment and Treatment of Patients With Coexisting Mental Illness and Alcohol and Other Drug Abuse—<i>Replaced by TIP 42</i></p> <p>TIP 10 Assessment and Treatment of Cocaine-Abusing Methadone-Maintained Patients—
<i>Replaced by TIP 43</i></p> <p>TIP 11* Simple Screening Instruments for Outreach for Alcohol and Other Drug Abuse and Infectious Diseases—BKD143
Quick Guide for Clinicians QGCT11
KAP Keys for Clinicians KAPT11</p> <p>TIP 12 Combining Substance Abuse Treatment With Intermediate Sanctions for Adults in the Criminal Justice System—<i>Replaced by TIP 44</i></p> <p>TIP 13 Role and Current Status of Patient Placement Criteria in the Treatment of Substance Use Disorders—BKD161
Quick Guide for Clinicians QGCT13
Quick Guide for Administrators QGAT13
KAP Keys for Clinicians KAPT13</p> |
|--|---|

*Under revision

- TIP 14 Developing State Outcomes Monitoring Systems for Alcohol and Other Drug Abuse Treatment**—BKD162
- TIP 15 Treatment for HIV-Infected Alcohol and Other Drug Abusers**—*Replaced by TIP 37*
- TIP 16 Alcohol and Other Drug Screening of Hospitalized Trauma Patients**—BKD164
Quick Guide for Clinicians QGCT16
KAP Keys for Clinicians KAPT16
- TIP 17 Planning for Alcohol and Other Drug Abuse Treatment for Adults in the Criminal Justice System**—*Replaced by TIP 44*
- TIP 18 The Tuberculosis Epidemic: Legal and Ethical Issues for Alcohol and Other Drug Abuse Treatment Providers**—BKD173
Quick Guide for Clinicians QGCT18
KAP Keys for Clinicians KAPT18
- TIP 19 Detoxification From Alcohol and Other Drugs**—*Replaced by TIP 45*
- TIP 20 Matching Treatment to Patient Needs in Opioid Substitution Therapy**—*Replaced by TIP 43*
- TIP 21 Combining Alcohol and Other Drug Abuse Treatment With Diversion for Juveniles in the Justice System**—(SMA) 08-4073
Quick Guide for Clinicians and Administrators QGCA21
- TIP 22 LAAM in the Treatment of Opiate Addiction**—*Replaced by TIP 43*
- TIP 23 Treatment Drug Courts: Integrating Substance Abuse Treatment With Legal Case Processing**—(SMA) 08-3917
Quick Guide for Administrators QGAT23
- TIP 24 A Guide to Substance Abuse Services for Primary Care Clinicians**—(SMA) 08-4075
Concise Desk Reference Guide BKD123
Quick Guide for Clinicians QGCT24
KAP Keys for Clinicians KAPT24
- TIP 25 Substance Abuse Treatment and Domestic Violence**—(SMA) 08-4076
Linking Substance Abuse Treatment and Domestic Violence Services: A Guide for Treatment Providers MS668
Linking Substance Abuse Treatment and Domestic Violence Services: A Guide for Administrators MS667
Quick Guide for Clinicians QGCT25
KAP Keys for Clinicians KAPT25
- TIP 26 Substance Abuse Among Older Adults**—(SMA) 08-3918
Substance Abuse Among Older Adults: A Guide for Treatment Providers MS669
Substance Abuse Among Older Adults: A Guide for Social Service Providers MS670
Substance Abuse Among Older Adults: Physician's Guide MS671
Quick Guide for Clinicians QGCT26
KAP Keys for Clinicians KAPT26
- TIP 27 Comprehensive Case Management for Substance Abuse Treatment**—(SMA) 08-4215
Case Management for Substance Abuse Treatment: A Guide for Treatment Providers MS673
Case Management for Substance Abuse Treatment: A Guide for Administrators MS672
Quick Guide for Clinicians QGCT27
Quick Guide for Administrators QGAT27
- TIP 28* Naltrexone and Alcoholism Treatment**—*Replaced by TIP 49*
- TIP 29 Substance Use Disorder Treatment for People With Physical and Cognitive Disabilities**—(SMA) 08-4078
Quick Guide for Clinicians QGCT29
Quick Guide for Administrators (SMA) 08-3592
KAP Keys for Clinicians KAPT29
- TIP 30 Continuity of Offender Treatment for Substance Use Disorders From Institution to Community**—(SMA) 08-3920
Quick Guide for Clinicians QGCT30
KAP Keys for Clinicians KAPT30
- TIP 31 Screening and Assessing Adolescents for Substance Use Disorders**—(SMA) 08-4079
See companion products for TIP 32.
- TIP 32 Treatment of Adolescents With Substance Use Disorders**—(SMA) 08-4080
Quick Guide for Clinicians QGC312
KAP Keys for Clinicians KAP312
- TIP 33 Treatment for Stimulant Use Disorders**—(SMA) 06-4209
Quick Guide for Clinicians QGCT33
KAP Keys for Clinicians KAPT33

*Under revision

- TIP 34 Brief Interventions and Brief Therapies for Substance Abuse**—(SMA) 07-3952
Quick Guide for Clinicians QGCT34
KAP Keys for Clinicians KAPT34
- TIP 35 Enhancing Motivation for Change in Substance Abuse Treatment**—(SMA) 08-4212
Quick Guide for Clinicians QGCT35
KAP Keys for Clinicians KAPT35
- TIP 36 Substance Abuse Treatment for Persons With Child Abuse and Neglect Issues**—(SMA) 08-3923
Quick Guide for Clinicians QGCT36
KAP Keys for Clinicians KAPT36
Helping Yourself Heal: A Recovering Woman's Guide to Coping With Childhood Abuse Issues (SMA) 08-4132
Available in Spanish: PHD981S
Helping Yourself Heal: A Recovering Man's Guide to Coping With the Effects of Childhood Abuse (SMA) 08-4134
Available in Spanish: PHD1059S
- TIP 37 Substance Abuse Treatment for Persons With HIV/AIDS**—(SMA) 08-4137
Quick Guide for Clinicians MS678
KAP Keys for Clinicians KAPT37
Drugs, Alcohol, and HIV/AIDS: A Consumer Guide (SMA) 08-4127
Drugs, Alcohol, and HIV/AIDS: A Consumer Guide for African Americans (SMA) 07-4248
- TIP 38 Integrating Substance Abuse Treatment and Vocational Services**—(SMA) 06-4216
Quick Guide for Clinicians QGCT38
Quick Guide for Administrators QGAT38
KAP Keys for Clinicians KAPT38
- TIP 39 Substance Abuse Treatment and Family Therapy**—(SMA) 08-4219
Quick Guide for Clinicians QGCT39
Quick Guide for Administrators QGAT39
- TIP 40 Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction**—(SMA) 07-3939
Quick Guide for Physicians QGPT40
KAP Keys for Physicians KAPT40
- TIP 41 Substance Abuse Treatment: Group Therapy**—(SMA) 05-3991
Quick Guide for Clinicians QGCT41
- TIP 42 Substance Abuse Treatment for Persons With Co-Occurring Disorders**—(SMA) 08-3992
Quick Guide for Clinicians (SMA) 07-4034
Quick Guide for Administrators QGAT42
KAP Keys for Clinicians (SMA) 08-4036
- TIP 43 Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs**—(SMA) 08-4214
Quick Guide for Clinicians QGCT43
KAP Keys for Clinicians (SMA) 07-4108
- TIP 44 Substance Abuse Treatment for Adults in the Criminal Justice System**—(SMA) 05-4056
Quick Guide for Clinicians QGCT44
KAP Keys for Clinicians (SMA) 07-4150
- TIP 45 Detoxification and Substance Abuse Treatment**—(SMA) 08-4131
Quick Guide for Clinicians (SMA) 06-4225
KAP Keys for Clinicians (SMA) 06-4224
Quick Guide for Administrators (SMA) 06-4226
- TIP 46 Substance Abuse: Administrative Issues in Outpatient Treatment**—(SMA) 06-4157
Quick Guide for Administrators (SMA) 07-4232
- TIP 47 Substance Abuse: Clinical Issues in Outpatient Treatment**—(SMA) 06-4182
Quick Guide for Clinicians (SMA) 07-4233
KAP Keys for Clinicians (SMA) 07-4251
- TIP 48 Managing Depressive Symptoms in Substance Abuse Clients During Early Recovery**—(SMA) 08-4353
- TIP 49 Incorporating Alcohol Pharmacotherapies Into Medical Practice**—(SMA) 09-4380
Quick Guide for Counselors (SMA) 10-4542
KAP Keys for Clinicians (SMA) 10-4544
Quick Guide for Physicians (SMA) 10-4543
- TIP 50 Addressing Suicidal Thoughts and Behaviors in Substance Abuse Treatment**—(SMA) 09-4381
- TIP 51 Substance Abuse Treatment: Addressing the Specific Needs of Women**—(SMA) 09-4426

*Under revision

TIP 52 Clinical Supervision and Professional Development of the Substance Abuse Counselor—(SMA) 09-4435

TIP 53 Addressing Viral Hepatitis in People With Substance Use Disorders—(SMA) 11-4656

TIP 54 Managing Chronic Pain in Adults With or in Recovery From Substance Use Disorders—(SMA) 12-4671

HHS Publication No. (SMA) 11-4656
Printed 2011

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Center for Substance Abuse Treatment
www.ASAMTraining.com

www.ASITraining.com

www.ASITrainingOnline.com